Related by context. All words. (Click for frequent words.) 60 AEZS 60 CRx 60 ISIS # 60 SRT# [003] 60 AEGR 59 PRTX 58 preclinical efficacy 58 preclinically 57 MORAb 57 CERE 57 favorable pharmacokinetic profile 57 INGN 57 GFT# 57 NKTR 57 ARRY 56 ITMN 56 Phase #b/#a 56 tanespimycin 56 DP b# 56 antisense drug 56 Symadex 56 iCo 56 INCB# [001] 56 metaglidasen 55 Archexin 55 PSN# [002] 55 ALTU 55 Bezielle 55 ProSavin 55 HCV protease inhibitors 55 phase IIa clinical 55 CUDC 55 Phase Ib clinical 55 cannabinor 55 Lu AA# 55 liposomal formulation 55 eniluracil 55 alagebrium 54 oral FTY# 54 ANG# 54 CRLX# 54 Varespladib 54 ORMD 54 Phase Ib study 54 Debio 54 pharmacokinetic PK 54 obatoclax 54 OXi# 54 IPL# 54 phase IIb clinical 54 orally bioavailable 54 IRX 2 54 clinical pharmacology studies 53 XmAb# 53 BIBW 53 Phase 2a clinical 53 TRO# 53 APOPTONE 53 CA4P 53 SABCS 53 bardoxolone 53 R#/MEM # 53 Sym# 53 pharmacokinetic PK profile 53 Virulizin ® 53 solithromycin 53 Phase IIa clinical 53 pharmacokinetic pharmacodynamic 53 otelixizumab 53 Azedra 53 JAK inhibitor 53 pharmacokinetics PK 53 decitabine 53 PXD# 53 PS# [001] 53 pan HDAC inhibitor 53 OHR/AVR# 53 PEG SN# 53 depsipeptide 53 CIMZIA TM 53 CBLC# 53 Phase IIa trials 53 Phase 1b 53 oral prodrug 53 celgosivir 52 viral kinetic 52 ThGRF 52 Cethromycin 52 AAG geldanamycin analog 52 histone deacetylase HDAC inhibitor 52 Phase 1b trial 52 AEG# 52 APPRAISE 52 CYT# 52 EOquin TM 52 Mipomersen 52 elotuzumab 52 REG2 52 ALKS 52 vascular disrupting agent 52 MT# MEDI 52 PROSTVAC TM 52 Phase IIB 52 Traficet EN 52 orally administered inhibitor 52 MEDI 52 telaprevir VX 52 Elocalcitol 52 MEK inhibitors 52 phase IIb 52 ganetespib 52 GAP #B# 52 HuMax EGFr 52 enzastaurin 52 ON #.Na 52 HCV protease inhibitor 52 ATL# [001] 51 ELND# AZD 51 CCX# 51 Onconase 51 BAY #-# 51 RG# ITMN 51 Tyrima 51 randomized discontinuation trial 51 ADXS# 51 HQK 51 EORTC 51 HspE7 51 picoplatin 51 forodesine 51 antithrombotic 51 BCIRG 51 INCB# [002] 51 lomitapide 51 TG MV 51 preclinical studies 51 alvespimycin 51 Triolex 51 HIF PHI 51 vascular disrupting agents 51 TBC# 51 CoFactor 51 vidofludimus 51 teriflunomide 51 anti amnesic 51 pertuzumab 51 HuMax CD4 51 R#/MEM 51 SUVN 51 Tanespimycin 51 IMGN# 51 Kahalalide F 51 HCV NS5B polymerase 51 dexpramipexole 51 Phase #/#a 51 Carfilzomib 51 Bicifadine 51 Cloretazine ® 51 perifosine 51 VAPRISOL 51 riociguat 51 anticoagulant reversing agent 51 LUX Lung 51 polymerase inhibitor 51 XL# [003] 50 ATHX 50 rFIXFc 50 CR# vcMMAE 50 axitinib 50 Antiviral Activity 50 YONDELIS 50 XOMA 50 BrachySil TM 50 darapladib 50 elacytarabine 50 4SC 50 brivaracetam 50 preclinical 50 EndoTAG TM -1 50 ELND# 50 AVN# [001] 50 mertansine 50 Phase IIa trial 50 Zemiva 50 Viprinex 50 novel VDA molecule 50 deforolimus 50 pharmacokinetic PK study 50 CGEN # 50 pitavastatin 50 Nanobody 50 tolerability profiles 50 Phenoptin 50 Phase IIb trials 50 phase IIb study 50 TRX1 50 thymalfasin 50 HGS ETR1 50 phase IIa 50 PRT# 50 AKT inhibitor 50 Phase Ib II 50 PSMA ADC 50 Phase 2a 50 Asentar 50 JAK inhibitors 50 MAGE A3 ASCI 50 tesmilifene 50 Synavive 50 initiate Phase 1b 50 ALN TTR 50 MEK inhibitor 50 amrubicin 50 Civacir 50 CCR9 antagonist 50 Factor VIIa 50 ulimorelin 50 torezolid phosphate 50 aleglitazar 50 farletuzumab 50 belinostat 50 IDX# 50 Perifosine 50 VQD 49 ocrelizumab 49 HyQ 49 atacicept 49 HuMax CD# 49 Phase #b/#a clinical 49 Anticalin R 49 vinca alkaloid 49 XL# SAR# 49 MGCD# [001] 49 EGS# 49 PEG PAL 49 Gemin X 49 investigational humanized monoclonal antibody 49 dose cohort 49 nonclinical studies 49 Phase #b/#a trial 49 PCK# 49 Diasome 49 iSONEP 49 Nanobody ® 49 bendamustine 49 Reverset 49 JAK2 inhibitor 49 EndoTAG 49 ATL/TV# 49 TMC# [002] 49 DPP4 inhibitor 49 generation antisense 49 Amigal 49 Phase 2b 49 placebo controlled clinical 49 Anticalin ® 49 Cethrin 49 ANX 49 ESBATech 49 IAP inhibitors 49 PHX# 49 Phase Ib 49 blinatumomab 49 dose escalation trial 49 nicotinic alpha 7 49 clevidipine 49 LibiGel Phase III 49 DAVANAT ® 49 Xanafide 49 targeting CD# 49 Panzem 49 brostallicin 49 Exelixis compounds 49 PEG Interferon lambda 49 custirsen 49 Guanilib 49 NexACT 49 Cotara 49 darinaparsin ZIO 49 PLX# 49 ASCO abstract 49 PreCISe 49 HCV SPRINT 49 ELACYT 49 multicenter trials 49 Omacetaxine 49 multicenter Phase 49 Locteron 49 anticancer compound 49 Chemophase 49 naproxcinod 49 GLPG# 49 glufosfamide 49 eltrombopag 49 OMP #M# 49 Actilon 48 Alpharadin 48 lesinurad 48 GSK # 48 RhuDex ® 48 randomized Phase 2b 48 Orazol 48 Relivar 48 Syncria 48 proteasome inhibitor 48 tafamidis 48 antitumor activity 48 phase 2a 48 Zybrestat 48 talactoferrin 48 Oral NKTR 48 non nucleoside inhibitor 48 Opexa 48 synthetic retinoid 48 evaluating tivozanib 48 R roscovitine 48 LymphoStat B 48 PROactive Study 48 HORIZONS AMI trial 48 investigational compounds 48 OncoVEX 48 Tovaxin 48 EGFR HER2 48 EndoTAGTM 1 48 ZYBRESTAT 48 MAXY alpha 48 EnVivo 48 aclidinium bromide 48 Celator 48 oral ridaforolimus 48 Cetrorelix 48 bicifadine 48 TKM ApoB 48 Neuradiab 48 OncoVEX GM CSF 48 CD# antibody [001] 48 Panzem R NCD 48 phase Ib 48 CEQ# 48 Amrubicin 48 Randomized Phase 48 XL# XL# XL# 48 ONTARGET 48 HGS ETR2 48 Tezampanel 48 IMC A# 48 trabectedin 48 neratinib 48 mRCC 48 INNO 48 IMC #B 48 sorafenib Nexavar 48 selective androgen receptor modulator 48 pain palliation 48 Nuvion 48 PROMACTA 48 Virulizin R 48 huC# DM4 48 selective androgen receptor modulators 48 atrasentan 48 Amplimexon 48 relapsed refractory multiple myeloma 48 Bortezomib 48 RGB # 48 Targretin 48 GALNS 48 NO# [002] 47 afatinib 47 HDAC Inhibitor 47 seliciclib CYC# 47 Aflibercept 47 palifosfamide 47 FOLOTYN ® 47 PRX # 47 Liprostin 47 oral antiviral 47 Pervasis 47 lumiliximab 47 standard chemotherapy regimen 47 betrixaban 47 Doxil ® 47 L BLP# 47 ZACTIMA 47 AASLD Meeting 47 Olmesartan 47 ISTH 47 DAVANAT R 47 Pertuzumab 47 Phase 1a 47 fostamatinib 47 clinical trial 47 iniparib 47 Ceflatonin R 47 lixivaptan 47 generation proteasome inhibitor 47 ponatinib 47 HuLuc# 47 PDE4 inhibitor 47 PNT# 47 trastuzumab emtansine T DM1 47 Æterna Zentaris 47 midstage clinical 47 TOPIGEN 47 Dacogen injection 47 GRN#L 47 Allovectin 7 R 47 KRN# 47 ACCORD Lipid 47 prostone 47 GW# [003] 47 Resolvyx 47 cMET 47 Angiolix 47 CIMZIA ™ 47 Plicera 47 Aplidin 47 seliciclib 47 HCV polymerase inhibitor 47 sapacitabine 47 Ecallantide 47 Behcet uveitis 47 ongoing Phase 1b 47 methylnaltrexone 47 valopicitabine 47 trastuzumab DM1 T DM1 47 compound AEZS 47 DAVANAT 47 adecatumumab 47 HCV protease 47 ProLindac 47 PRX# 47 Phase Ia 47 Tamibarotene 47 EASL 47 IMP# 47 ENMD 47 XL# XL# XL# XL# 47 SUCCEED trial 47 Ceflatonin 47 LymphoStat B TM 47 dose escalation clinical 47 romidepsin 47 PORxin TM 47 Neuraltus 47 mitogen activated ERK kinase 47 BZL# 47 ruxolitinib 47 Daclizumab 47 Hsp# Inhibitor 46 mg administered orally 46 SPIRIT IV 46 Quinamed 46 proteasome inhibitors 46 HIV integrase inhibitor 46 NEVO RES 46 AQ4N 46 relapsed multiple myeloma 46 imetelstat 46 AASLD 46 Natalizumab 46 XL# XL# 46 sunitinib 46 ImmunoVEX HSV2 46 IDEV 46 ASCO Annual Meeting 46 sipuleucel T 46 vosaroxin 46 pazopanib 46 GRN# 46 RhuDex 46 TACI Ig 46 CALGB 46 TPI ASM8 46 Phase III psoriasis 46 omega interferon 46 eritoran 46 ENDEAVOR III 46 Azixa 46 Alocrest 46 non nucleoside HCV 46 rALLy clinical trial 46 NCIC CTG 46 Lupuzor 46 JAK1 46 Blinatumomab 46 Sulonex TM 46 elvucitabine 46 targeted radiotherapeutic 46 Gastrointestinal Cancers Symposium 46 MDV# 46 BRAF inhibitor 46 Epothilone D 46 DPX Survivac 46 INCB# [003] 46 ICA # 46 sunitinib malate 46 polymerase inhibitors 46 MEND CABG 46 clusterin 46 Phase III HEAT 46 Prestara 46 pharmacogenetic 46 KineMed 46 immatics 46 CLARITY study 46 vilazodone 46 Phase IIa clinical trials 46 AACR NCI EORTC 46 Allovectin 7 ® 46 telcagepant 46 RE LY 46 ixabepilone 46 AzaSite Plus 46 Ron Bentsur 46 randomized controlled Phase 46 Sapacitabine 46 cathepsin K inhibitor 46 preclinical toxicology 46 motesanib diphosphate 46 carfilzomib 46 rALLy trial 46 ProMune 46 BRIM3 46 DOS# 46 AcelRx 46 AVEO 46 teplizumab 46 SUTENT ® 46 Maribavir 46 bortezomib Velcade 46 AEterna 46 ICAAC 46 Tesetaxel 46 NSABP 46 Icatibant 46 oritavancin 45 NCCTG N# 45 Vilazodone 45 rilonacept 45 Enzastaurin 45 cancer immunotherapies 45 ThermoDox R 45 ILLUMINATE 45 Lorianne Masuoka MD 45 PANVAC VF 45 pradefovir 45 Eniluracil 45 antiplatelet 45 lintuzumab 45 EVEREST II 45 PSN# [001] 45 ALLHAT 45 BiTE R 45 SU# [003] 45 AP# [003] 45 TOCOSOL Paclitaxel 45 A3 adenosine receptor 45 bosutinib 45 Diabetologia 45 Tavocept 45 alemtuzumab Campath 45 multicenter clinical 45 YONDELIS R 45 Excellagen 45 Clinical Oncology Annual Meeting 45 PBTH 45 antibody MAb 45 Nanobodies 45 anti angiogenic agents 45 Allovectin 7 45 Tesmilifene 45 ROCKET AF 45 ALN VSP 45 PIGF 45 Theratope 45 ISHLT 45 Arqule 45 Keryx Biopharma 45 Removab 45 Dr. Yatscoff 45 MOZOBIL 45 Solid Tumors 45 Celgosivir 45 cediranib 45 entinostat 45 tramiprosate Alzhemed TM 45 RG# [001] 45 Valopicitabine 45 elesclomol 45 Thorough QT 45 Pemetrexed 45 CUSTOM III 45 SAR# [004] 45 Seliciclib 45 Exelixis XL# 45 Hedgehog antagonist 45 mipomersen 45 ACHN 45 CROI 45 prostate cancer mCRPC 45 Antisense 45 ToGA 45 EuroPCR 45 NXL# 45 Ocrelizumab 45 GVAX 45 voreloxin 45 Abiraterone 45 CeNeS 45 Harbor BioSciences 45 omacetaxine 45 Tarvacin 45 motesanib 45 NCCTG 45 therapeutic monoclonal antibodies 45 Aegera Therapeutics 45 highly selective adenosine 45 ADVEXIN 45 Ambrisentan 45 satraplatin Phase 45 Glybera R 45 Phase III ALLEGRO 45 Abstract # 45 Atiprimod 45 Insegia 45 dirucotide 45 evaluating REVLIMID 45 OvaRex R 45 vandetanib 45 #th Annual Interscience 45 metastatic hormone refractory 45 assessing T DM1 45 Certican 45 perifosine KRX 45 Mr. Kriegsman 44 Kantarjian 44 Inflazyme 44 TASKi2 44 Clavis Pharma 44 palonosetron 44 Teplizumab 44 MKC# MKC# PP 44 Phase #/#a trial 44 Angiocept 44 CINTREDEKIN BESUDOTOX 44 ISPOR 44 TASQ 44 IMPACT IMmunotherapy 44 Dose Escalation 44 EFAPROXYN 44 refractory multiple myeloma 44 randomized Phase III 44 Prostate AdenoCarcinoma Treatment 44 NSABP C 44 RP# [002] 44 ECTRIMS 44 GRNVAC1 44 trastuzumab Herceptin 44 Semafore 44 Aegera 44 tesetaxel 44 TAXUS ATLAS 44 talabostat 44 TroVax ® 44 Potelligent Technology 44 UVIDEM 44 antiangiogenic therapy 44 mAb 44 IV Busulfex 44 adult chronic ITP 44 MGCD# [002] 44 CALGB # [002] 44 Deforolimus 44 #D#C# 44 AVADO 44 SCOLR Pharma 44 Dasatinib 44 Fabry Disease 44 durable pain palliation 44 daclizumab 44 Ramoplanin 44 bremelanotide 44 PEG INTRON 44 gemcitabine cisplatin 44 recurrent GBM 44 multicenter randomized Phase 44 Cloretazine R VNP#M 44 oral Xeloda 44 Corautus 44 Proxinium TM 44 SYNTAX trial 44 BioNumerik 44 RNA interference RNAi therapeutics 44 Aquinox 44 Vitaxin 44 Anthim 44 Telaprevir 44 panitumumab 44 CLL8 44 Selexis 44 ASBMR 44 Bapineuzumab 44 bavituximab 44 CD3 monoclonal antibody 44 faropenem 44 EyeGate 44 P#X# antagonist 44 SPIRIVA HandiHaler 44 HCV Protease Inhibitor 44 Xinlay 44 Mr. Bentsur 44 Panitumumab 44 nd Annual Meeting 44 Aegerion 44 Celsion Corporation 44 LymphoStat B belimumab 44 MAXY VII 44 WILEX 44 ASCO 44 registrational Phase 44 PLK1 SNALP 44 abstracts summarizing 44 Dr. Pingpank 44 Genfit 44 peginesatide 44 Anthera 44 Oasmia 44 Hyphanox 44 metastatic renal cell carcinoma 44 PIX# [002] 44 Protexia R 44 BARACLUDE R 44 CARE HF 44 Affitech 44 EORTC NCI AACR 44 anti CD# antibodies 44 Medidur FA 44 elinogrel 44 dutogliptin 44 Late Breaker 43 Randomized Phase II 43 clinical 43 Talabostat 43 CVac 43 OGX 43 TRAIL Receptor 43 Phase III 43 PERSEUS 43 Onalta 43 Bionovo 43 anti angiogenic therapy 43 TAXUS IV 43 GPR# agonist 43 BARI 2D 43 3SBio 43 ThermoDox ® 43 Anavex 43 Sosei 43 TKB# 43 LHRH antagonist 43 Oramed 43 bazedoxifene 43 Ixempra 43 Zalbin 43 Cloretazine R 43 IRESSA 43 NASDAQ CYTK announced 43 Molecular Insight 43 Targeted Chemotherapy 43 ENDEAVOR IV 43 NASDAQ CXSP announced 43 abiraterone acetate 43 Vandetanib 43 Kuvan 43 SIR Spheres 43 VEGF Trap 43 Daniel Von Hoff 43 Unit Dose Budesonide 43 Velcade bortezomib 43 Nasdaq IDRA today 43 Dendreon Provenge 43 abiraterone 43 ovarian suppression 43 ACRIN 43 Cellgate 43 PRECISE 43 HuMax TAC 43 recurrent GBM patients 43 Phase III TRIST 43 Chemokine 43 Cortex Pharmaceuticals 43 Tranzyme 43 RTOG 43 Dr. Scangos 43 neoadjuvant treatment 43 CD# CEA 43 Neuvenge 43 DSMB 43 Versartis 43 EASD 43 Dr. Von Hoff 43 SCYNEXIS 43 including eniluracil ADH 43 SCCHN 43 IMMU 43 ENZON 43 Fibrillex TM 43 Rigel Pharma 43 Hematology Meeting 43 satraplatin 43 GSK '# 43 Pixuvri 43 EULAR 43 CD# monoclonal antibody 43 ABCSG 43 Zerenex ™ 43 cabozantinib 43 BRIM2 43 Tolerx 43 Nymox 43 Virulizin 43 Dr. Ayalew Tefferi 43 BioGeneriX 43 KRAS status 43 cetuximab Erbitux 43 Revlimid lenalidomide 43 daptomycin 43 Clinical Trial Results 43 SARcode 43 glucokinase activator 43 NASDAQ LGND 43 Acologix 43 Zarnestra 43 Symphogen 43 panobinostat 43 Oncogenex 43 Therapeutics TCT scientific 43 Adventrx 43 ELCAP 43 ORAL Sync 43 NABTT 43 entitled Synergistic 42 Daniel Junius 42 Cardiology ESC 42 Xelox 42 Dr. McHutchison 42 PROLARIS 42 trastuzumab DM1 42 Biotie 42 Taxotere ® 42 Temsirolimus 42 Glufosfamide 42 ISEL 42 PROSTVAC ® 42 ISA# [002] 42 Hexvix 42 Addex 42 HER2 positive metastatic breast 42 Hormone Refractory Prostate Cancer 42 ASH Annual Meeting 42 ACC AHA 42 Nexavar sorafenib 42 Nippon Shinyaku 42 aflibercept 42 oncology therapeutics 42 ADA Scientific Sessions 42 PARTNER Trial 42 pralatrexate 42 GammaCan 42 #th Interscience Conference 42 Synta Pharmaceuticals 42 AACR Annual Meeting 42 ASHG 42 ACUITY trial 42 dacetuzumab 42 Syntonix 42 randomized Phase IIb 42 Ardea Biosciences 42 Clinical Trial Data 42 clusterin protein 42 FOLOTYN 42 AVAX 42 VentiRx 42 CTRC AACR San Antonio 42 RECORD1 42 Nasdaq OPTR 42 NovoTTF 42 NRGN 42 Novelos 42 Pirfenidone 42 Nasdaq ACHN 42 Diatos 42 TNFerade 42 Nventa 42 Arisaph 42 #nd EORTC NCI 42 EXPAREL ™ 42 ENESTnd 42 Phase III VISTA 42 Entremed 42 investigational immunotherapy 42 NovaDel 42 EORTC NCI AACR Symposium 42 mTOR inhibition 42 NEUVENGE 42 Combination REOLYSIN R 42 Sulonex 42 telomerase therapeutic 42 brentuximab vedotin SGN 42 sunitinib Sutent 42 Promacta 42 NSCLC 42 danoprevir 42 evaluable patients 42 Unither 42 Hematology Annual Meeting 42 Scientific Session 42 iclaprim 42 SWOG 42 Boceprevir 42 GENR 42 tasocitinib 42 Genta Incorporated OTCBB GETA 42 CAMMS# 42 enGene 42 TroVax 42 Everolimus 42 entecavir 42 Circ Pharma 42 Onrigin 42 metastatic renal cell 42 OPAXIO 42 Panacos 42 Taxotere R 42 Poster Discussion 42 Ligand 42 America HFSA 42 antisense drugs 42 drug conjugate 42 Cerimon 42 AACR symposium 42 PREOS R 42 Treanda 42 AIR2 Trial 42 LBH# 42 Hematology ASH 42 Annual Scientific Sessions 42 PhaseBio 42 AACR #st Annual Meeting 42 Kissei Pharmaceutical 41 RDEA 41 ChemGenex Pharmaceuticals Limited 41 DFCI 41 Sinobiopharma 41 Gastrotech 41 FermaVir 41 NTII 41 dalbavancin 41 Peregrine Pharmaceuticals 41 EnzymeRx 41 Mersana 41 STEDESA 41 Tocosol Paclitaxel 41 Relypsa 41 Steven B. Ratoff 41 Cempra 41 ESMO 41 Enanta 41 alogliptin 41 Hsp# protein 41 BR.# 41 ParAllele 41 Cytopia 41 ARVO 41 REOLYSIN ® 41 Keryx Biopharmaceuticals 41 Reolysin 41 InNexus Biotechnology 41 PharmaMar 41 pediatric acute lymphoblastic 41 ePRO 41 Lipoxen 41 Scancell 41 ASCO GI 41 ViRexx 41 FivePrime 41 DASISION 41 Amorfix 41 Annual ICAAC 41 ASA# 41 Progenics Pharmaceuticals 41 Novartis Zometa 41 BCR ABL inhibitors 41 ECCMID 41 Romidepsin 41 Vectibix 41 Anticancer Drug 41 Mtsare Khevi Field 41 Immunogen